Search

Showing total 5 results
Start Over Topic epidemiology Publication Year Range Last 3 years
5 results

1. Mid-childhood fat mass and airflow limitation at 15 years:The mediating role of insulin resistance and C-reactive protein

Author

Gabriela P. Peralta, Raquel Granell, Annabelle Bédard, Anne‐Elie Carsin, Elaine Fuertes, Laura D. Howe, Sandra Márquez, Deborah L. Jarvis, Judith Garcia‐Aymerich, CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Global - Institute For Global Health [Barcelona] (ISGlobal), Universitat Pompeu Fabra [Barcelona] (UPF), Universität Zürich [Zürich] = University of Zurich (UZH), University of Bristol [Bristol], Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Hospital del Mar Medical Research Institute [Barcelona, Spain] (IMIM), Imperial College London, Wellcome Trust, WT, Medical Research Council, MRC: 076467/Z/05/Z, G0401540/73080, Generalitat de Catalunya, Ministerio de Ciencia e Innovación, MICINN, Horizon 2020: 633212, The present analyses are part of the Aging Lungs in European Cohorts (ALEC) Study ( www.alecstudy.org ), which has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No. 633212. The content of this article reflects only the authors' views, and the European Commission is not liable for any use that may be made of the information contained therein. The UK Medical Research Council and Wellcome (Grant reference: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and Laura Howe and Raquel Granell will serve as guarantors for the contents of this paper. A comprehensive list of grant funding is available on the ALSPAC website ( http://www.bristol.ac.uk/alspac/external/documents/grant‐acknowledgements.pdf ). Specifically, grants from Wellcome Trust and MRC (076467/Z/05/Z and G0401540/73080) supported the collection of body composition and lung function data at 15 years. We acknowledge support from the Spanish Ministry of Science and Innovation through the 'Centro de Excelencia Severo Ochoa 2019–2023' Program (CEX2018‐000806‐S), and support from the Generalitat de Catalunya through the CERCA Program., European Project: 633212,H2020,H2020-PHC-2014-two-stage,ALEC(2015), HAL UVSQ, Équipe, and Aging Lungs in European Cohorts - ALEC - - H20202015-05-01 - 2019-04-30 - 633212 - VALID

Subjects
[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, obesity, Immunology, ALSPAC, C-reactive protein, [SDV.MHEP.PED] Life Sciences [q-bio]/Human health and pathology/Pediatrics, insulin resistance, Pediatrics, Perinatology and Child Health, Immunology and Allergy, epidemiology, mediation, airflow limitation
Abstract

Key MessageAlthough obesity measures have been consistently associated with a lower FEV1/FVC ratio in adolescents, no previous study has assessed the underlying mechanisms of this association This population-based study assessed whether insulin resistance and CRP levels at 15 years partially mediate the association between fat mass and FEV1/FVC using a causal mediation analysis approach. The findings suggest that insulin resistance at 15 years may mediate over 20% of this association, but no evidence of a mediating role of CRP was found. Further, longitudinal studies that evaluate other biomarkers of systemic inflammation and examine other potential mechanisms are needed to better understand the pathways linking obesity and respiratory health in adolescence. This is key for public health interventions and targeting clinical interventions.AbstractBackgroundWe previously reported an association of high fat mass levels from age 9 to 15 years with lower forced expiratory flow in 1 s (FEV1)/forced vital capacity (FVC) ratio (i.e., increased risk of airflow limitation) at 15 years. Here, we aimed to assess whether insulin resistance and C-reactive protein (CRP) at 15 years partially mediate this association.MethodsWe included 2263 children from the UK Avon Longitudinal Study of Parents and Children population-based cohort (ALSPAC). Four fat mass index (FMI) trajectories (“low,” “medium-low,” “medium-high,” “high”) from 9 to 15 years were previously identified using Group-Based Trajectory Modeling. Data on CRP, glucose, insulin, and post-bronchodilator FEV1/FVC were available at 15 years. We defined insulin resistance by the homeostasis model assessment-estimated insulin resistance index (HOMA-IR). We used adjusted linear regression models and a causal mediation analysis to assess the mediating role of HOMA-IR and CRP.ResultsCompared to children in the “low” FMI trajectory, children in the “medium-high” and “high” FMI trajectories had lower FEV1/FVC at 15 years. The percentage of the total effect explained by HOMA-IR was 19.8% [−114.1 to 170.0] and 20.4% [1.6 to 69.0] for the “medium-high” and “high” trajectories, respectively. In contrast, there was little evidence for a mediating role of CRP.ConclusionThe association between mid-childhood fat mass and FEV1/FVC ratio at 15 years may be partially mediated by insulin resistance.

Published
2022

2. Impact of the COVID-19 pandemic on total, sex- and age-specific all-cause mortality in 20 countries worldwide during 2020: results from the C-MOR project

Author

Christiana A Demetriou, Souzana Achilleos, Annalisa Quattrocchi, John Gabel, Elena Critselis, Constantina Constantinou, Nicoletta Nicolaou, Giuseppe Ambrosio, Catherine M Bennett, Nolwenn Le Meur, Julia A Critchley, Laust Hvas Mortensen, Jose Manuel Rodriguez-Llanes, Mario Chong, Gleb Denissov, Petra Klepac, Lucy P Goldsmith, Antonio José Leal Costa, Terje P Hagen, Marie Chan Sun, Qian Huang, Nataliia Pidmurniak, Inbar Zucker, Joseph Cuthbertson, Bo Burström, Manuel Barron, Ivan Eržen, Fabrizio Stracci, Wilson Calmon, Cyndy Martial, Olesia Verstiuk, Zalman Kaufman, Wenjing Tao, Maia Kereselidze, Nino Chikhladze, Antonis Polemitis, Andreas Charalambous, University of Nicosia, École des Hautes Études en Santé Publique [EHESP] (EHESP), Département Méthodes quantitatives en santé publique (METIS), Centre de Recherches sur l'Action Politique en Europe (ARENES), Université de Rennes (UR)-Institut d'Études Politiques [IEP] - Rennes-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Centre National de la Recherche Scientifique (CNRS), This work was supported by the University of Nicosia Medical School (internal funding). The funding source did not have any involvement in study design, the collection, analysis and interpretation of data, in the writing of the report, and or in the decision to submit the paper for publication.

Subjects
Pandemic, Epidemiology, SARS-CoV-2, COVID-19, Global impact, Infection control, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, General Medicine, Excess mortality, All-cause mortality
Abstract

Background To understand the impact of the COVID-19 pandemic on mortality, this study investigates overall, sex- and age-specific excess all-cause mortality in 20 countries, during 2020. Methods Total, sex- and age-specific weekly all-cause mortality for 2015–2020 was collected from national vital statistics databases. Excess mortality for 2020 was calculated by comparing weekly 2020 observed mortality against expected mortality, estimated from historical data (2015–2019) accounting for seasonality, long- and short-term trends. Crude and age-standardized rates were analysed for total and sex-specific mortality. Results Austria, Brazil, Cyprus, England and Wales, France, Georgia, Israel, Italy, Northern Ireland, Peru, Scotland, Slovenia, Sweden, and the USA displayed substantial excess age-standardized mortality of varying duration during 2020, while Australia, Denmark, Estonia, Mauritius, Norway, and Ukraine did not. In sex-specific analyses, excess mortality was higher in males than females, except for Slovenia (higher in females) and Cyprus (similar in both sexes). Lastly, for most countries substantial excess mortality was only detectable (Austria, Cyprus, Israel, and Slovenia) or was higher (Brazil, England and Wales, France, Georgia, Italy, Northern Ireland, Sweden, Peru and the USA) in the oldest age group investigated. Peru demonstrated substantial excess mortality even in the Conclusions This study highlights that excess all-cause mortality during 2020 is context dependent, with specific countries, sex- and age-groups being most affected. As the pandemic continues, tracking excess mortality is important to accurately estimate the true toll of COVID-19, while at the same time investigating the effects of changing contexts, different variants, testing, quarantine, and vaccination strategies.

Published
2022

3. Critical reappraisal of Balangero chrysotile and mesothelioma risk

Author

Yumi M Kumiya, Edward B. Ilgren, John A. Hoskins, Frederick D. Pooley, and Dr Ilgren wrote this paper when a Consultant to companies in asbestos litigation

Subjects
lcsh:R5-920, Epidemiology, business.industry, lcsh:Public aspects of medicine, lcsh:RA1-1270, Diagnostic accuracy, medicine.disease, Pleural disease, Cross matching, Tremolite Asbestos, Environmental health, Chrysotile, medicine, Amphibole asbestos, Tremolite, Mesothelioma, lcsh:Medicine (General), business
Abstract

BackgroundBalangero, 40 km northwest of Torino in the Piedmonte Region, was home to the largest and most active chrysotile mine in Europe operating from 1916 - 1990 and employed over 300 men at any one time. The chrysotile was thought to be pure. Despite this some claim it has been responsible for causing numerous mesotheliomas. This report refutes this claim on the grounds that it is not pure but potentially contaminated by tremolite asbestos. In addition there are numerous alternate sources of naturally occurring and commercially available amphibole asbestos in the region.MethodsGeological studies illustrate the presence of naturally occurring tremolite and various analyses have shown naturally occurring and commercially used amphibole its presence in animal and human tissue. The diagnostic criteria used to study pleural disease in the Balangero cohort were examined on a case by case basis. ResultsSeveral authors have searched available registries for post-mortem information and listed possible mesothelioma cases. Cross matching these searches has been attempted and the strength of their diagnoses examined. Conclusion.There is good evidence that crocidolite, amosite and tremolite are responsible for the alleged mesothelioma cases at Balangero. Myriad sources of naturally occurring and commercial amphibole asbestos exist in the region to account for the alleged cases. Regrettably, necessary information is incomplete and insufficient for the cohort which calls the diagnostic accuracy of the cases into question. The problem is further compounded by confusion surrounding job titles and raises the question if any of cases actually ever occurred in ‘miners’ per se.

Published
2022

4. Association between household cleaning product profiles evaluated by the Ménag'Score® index and asthma symptoms among women from the SEPAGES Cohort

Author

Lemire, Pierre, Chevallier, Emmanuel, Lyon-Caen, Sarah, Sévin, Etienne, Boudier, Anne, Pacheco Da Silva, Emilie, De Thuin, Christian, Slama, Rémy, Dumas, Orianne, Siroux, Valérie, Le Moual, Nicole, Eyriey, E., Licinia, A., Vellement, A., Pin, I., Hoffmann, P., Hullo, E., Llerena, C., Morin, X., Morlot, A., Lepeule, J., Lyon-Caen, S., Philippat, C., Quentin, J., Siroux, V., Slama, R., Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, National Institute for Consumption/Institut national de la consommation [Paris] (INC), Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) (IAB), Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), EpiConcept [Paris], This work was supported by the European Research Council under Grant N°311765-E-DOHaD, the European Community’s Seventh Framework Programme under Grant FP7/2007-206—N°308333-892 HELIX, the European Union’s Horizon 2020 research and innovation programme under Grants N° 874583 ATHLETE Project and N°825712 OBERON Project, the French Research Agency—ANR under Grants PAPER project ANR-12-PDOC-0029-01, SHALCOH project ANR-14-CE21-0007, ANR-15-IDEX-02 and ANR-15-IDEX5, GUMME project ANR-18-CE36-005 and ETAPE project ANR—EDeN project ANR -19-CE36-0003-01, the French Agency for Food, Environmental and Occupational Health & Safety—ANSES under Grants CNAP project EST-2016-121, PENDORE project EST-2016-121 and HyPAxE project EST-2019/1/039, the Plan Cancer under (Canc’Air project), the French Cancer Research Foundation Association de Recherche sur le Cancer—ARC, the French Endowment Fund AGIR for chronic diseases—APMC under Grants projects PRENAPAR and LCI-FOT, the French Endowment Fund for Respiratory Health, the French Fund—Fondation de France under Grants CLIMATHES—00081169 and SEPAGES 5—00099903, COBANET-Sepages project was supported by Anses and Ademe under Grants COBANET: Anses-PNR-EST-2015-1-022/Ademe-1594C0091and CRESPI: Anses-PNR-EST-2017-1-101/Ademe-1762C0021/ARS Ile de France 2018–2019: Pierre Lemire benefited from a PhD scholarship of the University of Paris-Sud/Paris-Saclay, France., SEPAGES Study Group: E Eyriey, A Licinia, A Vellement, I Pin, P Hoffmann, E Hullo, C Llerena, X Morin, A Morlot, J Lepeule, S Lyon-Caen, C Philippat, I Pin, J Quentin, V Siroux, R Slama., ANR-12-PDOC-0029,PAPER,Grossesse, pollution atmospherique, epigenetique, et sante respiratoire(2012), ANR-14-CE21-0007,SHALCOH,Expositions prénatales aux phénols et santé de l'enfant : analyse longitudinale(2014), ANR-11-RARE-0002,EDEN(2011), ANR-19-CE36-0003,EDeN,Exposition précoces aux perturbateurs endocriniens et neurodéveloppement de l'enfant : le rôle de l'axe hypothalamo-hypophysaire(2019), Faraldo, Beatrice, Retour Post-Doctorant - Grossesse, pollution atmospherique, epigenetique, et sante respiratoire - - PAPER2012 - ANR-12-PDOC-0029 - PDOC - VALID, Appel à projets générique - Expositions prénatales aux phénols et santé de l'enfant : analyse longitudinale - - SHALCOH2014 - ANR-14-CE21-0007 - Appel à projets générique - VALID, ERA RARE - - EDEN2011 - ANR-11-RARE-0002 - ERA RARE - VALID, and Exposition précoces aux perturbateurs endocriniens et neurodéveloppement de l'enfant : le rôle de l'axe hypothalamo-hypophysaire - - EDeN2019 - ANR-19-CE36-0003 - AAPG2019 - VALID

Subjects
Public health, household cleaning products, Epidemiology, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Public Health, Environmental and Occupational Health, Ménag'score, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, asthma
Abstract

International audience; Objective Considering household disinfectants and cleaning products (HDCP) as mixture of ingredients, rather than each ingredient individually, might help in characterizing their role in asthma. We investigated the association between HDCP and asthma, using the recently developed Ménag'Score®, a health risk assessment score based on exhaustive ingredient lists of HDCP. Methods The study is based on 103 female volunteers of the SEPAGES cohort (2014-2019), with repeated data (up to 3 collection times, 200 observations). HDCP use was assessed from a barcode-based smartphone application linked with an ingredient database. The Ménag'score® risks for health and environment were computed for each weekly used HDCP from their exhaustive ingredient data (from A: no known risk to E: highest risk). The association between the use of HDCP with a poor Ménag'score® (D or E; overall, health, environment scores) and asthma symptoms, was estimated by generalized estimating equations models adjusted for age, BMI and smoking status. Results Participants were on average 33 years old, 11% smoked and 20% had at least one asthma symptom. The Ménag'score® was computed for 540 HDCP scanned by participants. Weekly use of HDCP with a poor Ménag'score®-health (around 60% of the participants) was associated with a higher risk of asthma symptoms (OR=3.13, 95%CI:[1.32-7.43]). No association was observed for the Ménag'score®-environment. Conclusion The use of HDCP with a poor Ménag'score®-health was associated with asthma symptoms. The results support the use of the Ménag'score®-health to further evaluate the health risks of HDCP in observational studies and as a potential public health tool.

Published
2022

5. Statin Use and Skin Cancer Risk: A Prospective Cohort Study

Author

Trude Eid Robsahm, Agnès Fournier, Yahya Mahamat-Saleh, Reza Ghiasvand, Marina Kvaskoff, Manon Cairat, Marie-Christine Boutron-Ruault, Iris Cervenka, Marie Al Rahmoun, Gianluca Severi, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Oslo University Hospital [Oslo], Cancer Registry of Norway, International Agency for Cancer Research (IACR), Università degli Studi di Firenze = University of Florence (UniFI), 2102 918823, NCT03285230, Centre International de Recherche sur le Cancer, CIRC, Agence Nationale de la Recherche, ANR: ANR-10-COHO-0006, Institut National de la Santé et de la Recherche Médicale, Inserm, Institut National Du Cancer, INCa: INCa_13539, Institut Gustave-Roussy, Mutuelle Générale de l'Education Nationale, MGEN, We are grateful to the study participants for their continued participation and to practitioners for providing pathology reports. We also thank all members of the E3N study group, particularly Rafika Cha?t, Ghizlane Bajawi-Esselma, Amandine Gelot, Marie Fangon, Pascale Gerbouin-R?rolle, Sabine Moreira-Faria, Nad?ge Senina, Sofiane Harizi, Lyan Hoang, Anita Kowal, and Camille Laplanche for their technical assistance. The E3N cohort from the French National Institute of Health and Medical Research (Inserm) was supported by the Mutuelle G?n?rale de l'Education Nationale, the Gustave Roussy Institute, and the French League against Cancer. E3N-E4N is also supported by the French National Research Agency under the Investment for the Future Program (ANR-10-COHO-0006) and by the French Ministry of Higher Education, Research and Innovation (subsidy for public service charges #2102 918823). MAR, YMS, and IC were supported by research scholarships from the French National Cancer Institute (MAR: INCa_13539), the Paris Ile-de-France region, and the French Ministry of Research, respectively. This study is listed at ClinicalTrials.gov as NCT03285230. The work reported in this paper was performed during Agn?s Fournier's term as a Visiting Scientist at the International Agency for Research on Cancer. Conceptualization: MK, AF, Data Curation: MAR, AF, Formal Analysis: MAR, Funding Acquisition: MAR, MK, AF, Investigation: MAR, MK, AF, Methodology: MK, AF, Project Administration: MK, AF, Resources: GS, MCBR, MK, AF, Software: MAR, AF, Supervision: MK, AF, Visualization: MAR, Validation: MK, AF, Writing - Original Draft Preparation: MAR, RG, TER, MK, AF, Writing - Review and Editing: MAR, RG, MC, YMS, IC, GS, MCBR, TER, MK, AF, Funding sources had no role in study design, collection, analysis, and interpretation of data, writing of the report, and the decision to submit the article for publication., ANR-10-COHO-0006,E4N,Etude Epidémiologique des Enfants de femmes de l'Education Nationale(2010), HAL UVSQ, Équipe, and Cohortes - Etude Epidémiologique des Enfants de femmes de l'Education Nationale - - E4N2010 - ANR-10-COHO-0006 - COHO - VALID

Subjects
Male, medicine.medical_specialty, Skin Neoplasms, [SDV]Life Sciences [q-bio], [SDV.CAN]Life Sciences [q-bio]/Cancer, Dermatology, Biochemistry, Cohort Studies, [SDV.CAN] Life Sciences [q-bio]/Cancer, Risk Factors, Internal medicine, Epidemiology, medicine, Humans, Basal cell carcinoma, Prospective Studies, Prospective cohort study, Melanoma, Molecular Biology, Proportional Hazards Models, Aged, 80 and over, business.industry, Hazard ratio, Cell Biology, [SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatology, medicine.disease, Confidence interval, [SDV] Life Sciences [q-bio], Defined daily dose, Carcinoma, Basal Cell, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Carcinoma, Squamous Cell, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Skin cancer, business, Body mass index, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
Abstract

International audience; Epidemiological studies on statin use in relation to skin cancer risk are scarce and yielded conflicting results. We explored this association in Etude Epidémiologique auprès de femmes de l'Education Nationale, a prospective cohort of French women born in 1925–1950. Health and lifestyle data were self-reported biennially and matched with drug reimbursement data, allowing the identification of participants’ statin use since 2004. Multivariable cause-specific hazards regression models adjusted for skin cancer risk factors estimated hazard ratios with 95% confidence intervals. Over 2004–2014, 455 cutaneous melanoma, 1,741 basal cell carcinoma, and 268 squamous cell carcinoma cases were ascertained among 62,473 women. Compared with never use, there were no associations between ever use of statins and melanoma (hazard ratio = 1.16, 95% confidence interval = 0.94–1.44) or squamous cell carcinoma (hazard ratio = 0.89, 95% confidence interval = 0.66–1.19) risks and a decrease in basal cell carcinoma risk with ever use of statins (hazard ratio = 0.89, 95% confidence interval = 0.79–0.996). We found no trend of increasing or decreasing risks with dose, duration of use, time since first use, or age at first use and no statistically significant effect modification by pigmentary traits or residential UVR exposure. Because of the limited number of studies evaluating the associations between the use of statins and the risks of melanoma, basal cell carcinoma, and squamous cell carcinoma, these findings would deserve further investigation in other settings.

Published
2022